secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001070081-24-000015
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PTC Therapeutics Q2 revenue $187M; net loss narrows to $99M; NDAs submitted
---------------------------------------------------------------------------

- Q2 total revenue $186.7M vs $213.8M YoY; DMD franchise $118M (Translarna $70M, Emflaza $47M).
- Net loss $99.2M improved from $198.9M loss; cash $1.09B after $250M Royalty Pharma put option.
- Submitted NDA for sepiapterin (PKU) and resubmitted NDA for Translarna (nmDMD) to FDA in July 2024.
- Full-year 2024 revenue guidance $700M-$750M; GAAP R&D+SG&A $740M-$835M.
- BLA for AADC deficiency gene therapy accepted with priority review; PDUFA date Nov 13, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000107008124000015/0001070081-24-000015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000107008124000015/tmb-20240808x8k.htm
  HTML page:      https://secwatch.observer/filing/0001070081-24-000015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer